Title | Plasma Fractionation and Blood Transfusion [electronic resource] : Proceedings of the Ninth Annual Symposium on Blood Transfusion, Groningen, 1984, organized by the Red Cross Blood Bank Groningen-Drenthe / edited by C. Th. Smit Sibinga, P. C. Das, S. Seidl |
---|---|
Imprint | Boston, MA : Springer US, 1985 |
Connect to | http://dx.doi.org/10.1007/978-1-4613-2631-1 |
Descript | 250p. online resource |
I. Source material -- The future blood supply system in the USA: A prognosis -- Plasma supply. National and international logistics, whole blood versus plasmapheresis -- Processing criteria for recovery of FFP for fractionation -- Donation procedure: Collection lesion, fibrinopeptide A, and factor VIII -- Discussion -- II. Technology of plasma fractionation -- Small pool versus large pool in plasma fractionation: Reevaluation of a concept -- Ethanol fractionation of human plasma: An overview -- Control of large-scale plasma thawing -- Contributions to the optimization of factor VIII production: Cryoprecipitation and controlled pore glass adsorption -- Chromatographic methods of plasma fractionation -- Polyelectrolyte fractionation technology -- Recombinant DNA technology for the production of plasma proteins -- Column ion exchange chromatographic production of albumin, IV ISG and factor IX from 75,000 to 100,000 litres of plasma per year -- Large scale chromatographic experiments for plasma fractionation -- Discussion -- III. Safety aspects -- Preservation of structure and function during isolation of human plasma proteins -- The impact of donor selection of virus transmission -- Prevention of transmission of virus infections by blood transfusions and removal of virus infectivity from clotting factor concentrates -- Inactivation of hepatitis viruses (B, non-A/non-B) and retroviruses in pooled human plasma by means of ?-propiolactone-and UV-treatment -- HTLV-I/II and HTLV-III seroprevalence in blood product recipients -- Sero-epidemiology of the human T-lymphotropic retroviruses HTVL-I and HTLV-III in the Netherlands -- Discussion -- IV. Clinical aspects -- Needs, quality versus quantity -- Clinical characteristics of the factor VIII protein from various factor VIII concentrates -- Clinical use of polyelectrolyte-fractionated porcine factor VIII -- Factor VIII:C assay standardisation -- The current of status of fibronectin in clinical medical practice -- Intravenous use of gammaglobulin in 1984 -- Discussion